

RECEIVED  
CENTRAL FAX CENTER

SEP 23 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thai D. Nguyen *et al.*

Appln. No.: 09/227,881

Confirmation No.: 7578

Filed: January 11, 1999

Group Art Unit: 1635

Examiner: Schultz, James D.

For: *Nucleic Acids, Kits and Methods for the  
Diagnosis, Prognosis and Treatment of  
Glaucoma and Related Disorders*

Docket No.: 16491.066

## Interview Summary

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Interview Summary mailed September 15, 2004, Applicants submit the following summary.

Telephonic Interview, in Attendance:

Assistant Examiner: James D. Schultz

Registered Patent Agent: Joseph W. Ricigliano


- 1) Exhibits: None
- 2) Claims Discussed: None.
- 3) Cited Art Discussed: None
- 4) Amendments discussed: None
- 5) Summary: The Examiner contacted Applicants' representatives regarding the relationship of SEQ ID NO: 3 and SEQ ID NO: 34. Applicants' representatives indicated that based upon computer generated alignment of the two sequences it was their understanding that SEQ ID

NO: 34 was a fragment of SEQ ID NO: 3, and that the sequence were identical over the length of SEQ ID NO: 34. A copy of the computer generated sequences alignment of SEQ ID NO: 3 and SEQ ID NO: 34 listing the program and parameters employed for the alignment, which indicates 100% identity of SEQ ID NO: 34 with nucleotides 1-5271 of SEQ ID NO: 3, is attached. In the computer generated alignment, SEQ ID NO: 3 has been labeled as "Sequence 1" by the program, and SEQ ID NO: 34 has been labeled as "Sequence 2."

6) Other Matters: None

7) General Result: The Examiner indicated that as SEQ ID NO: 34 was a fragment of SEQ ID NO: 3, claims to both sequences would be examined in the next Office Action.

Respectfully submitted,



Joel M. Freed (Reg. Attorney No. 25,101)

David R. Marsh (Reg. Atty. No. 41,408 )

Joseph W. Ricigliano (Registered Patent Agent No. 48,511)

Date: September 23, 2004

ARNOLD & PORTER LLP

555 12<sup>th</sup> Street, N.W.

Washington, DC 20004

202.942.5000 telephone

202.942.5999 facsimile

I hereby certify that this transmittal letter and the listed documents are being facsimile transmitted to the attention of Group Art Unit 1635, via facsimile number (703) 872-9306



Joseph W. Ricigliano

September 23, 2004  
Date

# ARNOLD & PORTER LLP

202.942.5000  
202.942.5999 Fax

RECEIVED  
CENTRAL FAX CENTER

SEP 23 2004

555 Twelfth Street, NW  
Washington, DC 20004-1208

## Fax Transmittal

September 23, 2004

RECIPIENT NAME(S)	RECIPIENT FAX NUMBER(S)	RECIPIENT TELEPHONE NUMBER(S)	RECIPIENT ROOM #(S)
Examiner J. Douglas Shultz USPTO	703-872-9306	571-272-0760	
SENDER	SENDER'S TELEPHONE NUMBER	SENDER'S ROOM NUMBER	
Joseph Ricigliano	(202) 942-5174	988B	
CLIENT/MATTER NUMBER	TIMEKEEPER NUMBER	NUMBER OF PAGE(S)	
16491.066	6584	We are transmitting 13 page(s) (including this cover sheet)	
TRANSMISSION DEADLINE (DATE & TIME)		ALTERNATE TELEPHONE NUMBER (OPTIONAL)	
This document must be transmitted no later than: ASAP		Alternate telephone number at which the sender can be reached if there are difficulties with this fax: (202) 942-6498	
If you experience difficulty receiving this fax transmission, please contact the operator at 202.942.5837.			
Applicants: Thai D. NGUYEN <i>et al.</i> Appln. No.: 09/227,881 Filing Date: January 11, 1999 Title: Nucleic Acids, Kits and Methods for the Diagnosis, Prognosis and Treatment of Glaucoma and Related Disorders		Transmitted herewith are: 1. a Transmittal Letter; and 2. Interview Summary	

### PRIVILEGED AND CONFIDENTIAL

Information intended only for the use of the addressee named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, please note that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original message to us at the above address via the U.S. Mail.

---

ARNOLD & PORTER LLP

---

202.942.5000  
202.942.5999 Fax555 Twelfth Street, NW  
Washington, DC 20004-1206RECEIVED  
CENTRAL FAX CENTER

September 23, 2004

SEP 23 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attn: Mail Stop Amendment

Re: U.S. Patent Application No. 09/227,881  
Filed: January 11, 1999  
Title: *Nucleic Acids, Kits and Methods for the Diagnosis, Prognosis and Treatment of Glaucoma and Related Disorders*  
Applicants: Thai D. NGUYEN *et al.*  
Atty. Docket No.: 16491.066


Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (USPTO):

1. an Interview Summary.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387, referencing matter number 16491.066.


Respectfully submitted,



Joel M. Freed (Reg. Attorney No. 25,101)  
David R. Marsh (Reg. Attorney No. 41,408)  
Joseph W. Ricigliano (Reg. Agent No. 48,511)

## Attachments

I hereby certify that this transmittal letter and the listed documents are being facsimile transmitted to the attention of Group Art Unit 1635, via facsimile number (703) 872-9306.

  
Joseph W. RiciglianoSeptember 23, 2004  
Date